Search
- Aug 8, 2023
Tracking recent β-thal and CALD gene therapy launches with bluebird’s CEO
Andrew Obenshain describes key metrics bluebird is seeing early in the launch of two of its gene therapies on its Q2 earnings day.
Also look for unique social pages for BiotechTV U.
#1. Ultragenyx's Emil Kakkis on Angelman syndrome data, rare disease treatment modalities, and more
#2. The CEO of Madrigal on the launch of Rezdiffra for NASH liver disease
#3. Sutro Biopharma's CEO on ADCs, non-cell protein synthesis, and more
#4. Verve Therapeutics' CEO on today's gene editing clinical trial pause
#5. Daphne Zohar on becoming the CEO of Seaport Therapeutics and a $100M series A